J Antonio Aviña-Zubieta1, Kateryna Vostretsova2, Mary A De Vera3, Eric C Sayre4, Hyon K Choi5. 1. Division of Rheumatology, Department of Medicine, Arthritis Research Canada, University of British Columbia, Richmond, British Columbia, Canada; Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: azubieta@arthritisresearch.ca. 2. Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 3. Division of Rheumatology, Department of Medicine, Arthritis Research Canada, University of British Columbia, Richmond, British Columbia, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada. 4. Division of Rheumatology, Department of Medicine, Arthritis Research Canada, University of British Columbia, Richmond, British Columbia, Canada. 5. Division of Rheumatology, Department of Medicine, Arthritis Research Canada, University of British Columbia, Richmond, British Columbia, Canada; Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Abstract
OBJECTIVE: To estimate the future risk and time trends of newly diagnosed venous thromboembolism (VTE) in individuals with incident systemic lupus erythematosus (SLE) in the general population. METHODS: Using a population-based database that includes all residents of British Columbia, Canada we conducted a study cohort of all patients with incident SLE and up to 10 age-, sex-, and entry-time-matched individuals from the general population. We compared incidence rates of pulmonary embolism (PE), deep venous thrombosis (DVT), and VTE between the two groups according to SLE disease duration. We calculated hazards ratios (HR), adjusting for confounders. RESULTS: Among 4863 individuals with SLE (86% female; mean age, 48.9 years), the incidence rates (IRs) of PE, DVT, and VTE were 2.58, 3.33, and 5.32 per 1000 person-years, respectively, whereas the corresponding rates in the comparison cohort were 0.67, 0.57, and 1.11 per 1000 person-years. Compared with non-SLE individuals, the multivariable HRs among SLE patients were 3.04 (95% CI: 2.08-4.45), 4.46 (95% CI: 3.11-6.41), and 3.55 (95% CI: 2.69-4.69), respectively. The age-, sex-, and entry-time-matched HRs for PE, DVT, and VTE were highest during the first year after SLE diagnosis [13.57 (95% CI: 7.66-24.02), 11.13 (95% CI: 6.55-18.90), and 12.89 (95% CI: 8.56-19.41), respectively]. CONCLUSION: These findings provide population-based evidence that patients with SLE have a substantially increased risk of VTE, especially in the first year after SLE diagnosis. Awareness and increased vigilance of this potentially fatal, but preventable, complication is recommended.
OBJECTIVE: To estimate the future risk and time trends of newly diagnosed venous thromboembolism (VTE) in individuals with incident systemic lupus erythematosus (SLE) in the general population. METHODS: Using a population-based database that includes all residents of British Columbia, Canada we conducted a study cohort of all patients with incident SLE and up to 10 age-, sex-, and entry-time-matched individuals from the general population. We compared incidence rates of pulmonary embolism (PE), deep venous thrombosis (DVT), and VTE between the two groups according to SLE disease duration. We calculated hazards ratios (HR), adjusting for confounders. RESULTS: Among 4863 individuals with SLE (86% female; mean age, 48.9 years), the incidence rates (IRs) of PE, DVT, and VTE were 2.58, 3.33, and 5.32 per 1000 person-years, respectively, whereas the corresponding rates in the comparison cohort were 0.67, 0.57, and 1.11 per 1000 person-years. Compared with non-SLE individuals, the multivariable HRs among SLEpatients were 3.04 (95% CI: 2.08-4.45), 4.46 (95% CI: 3.11-6.41), and 3.55 (95% CI: 2.69-4.69), respectively. The age-, sex-, and entry-time-matched HRs for PE, DVT, and VTE were highest during the first year after SLE diagnosis [13.57 (95% CI: 7.66-24.02), 11.13 (95% CI: 6.55-18.90), and 12.89 (95% CI: 8.56-19.41), respectively]. CONCLUSION: These findings provide population-based evidence that patients with SLE have a substantially increased risk of VTE, especially in the first year after SLE diagnosis. Awareness and increased vigilance of this potentially fatal, but preventable, complication is recommended.
Authors: Mary A De Vera; Hyon Choi; Michal Abrahamowicz; Jacek Kopec; Maria Victoria Goycochea-Robles; Diane Lacaille Journal: Ann Rheum Dis Date: 2011-03-06 Impact factor: 19.103
Authors: Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes Journal: Medicine (Baltimore) Date: 2003-09 Impact factor: 1.889
Authors: Elisabet Svenungsson; Iva Gunnarsson; Vera Illescas-Bäckelin; Estelle Trysberg; Andreas Jönsen; Dag Leonard; Christopher Sjöwall; Susanne Pettersson Journal: Lupus Sci Med Date: 2021-05
Authors: Natalie McCormick; Kathryn Reimer; Ali Famouri; Carlo A Marra; J Antonio Aviña-Zubieta Journal: BMJ Open Date: 2017-06-21 Impact factor: 2.692
Authors: J Mofors; M Holmqvist; L Westermark; A Björk; M Kvarnström; H Forsblad-d'Elia; S Magnusson Bucher; P Eriksson; E Theander; T Mandl; M Wahren-Herlenius; G Nordmark Journal: J Intern Med Date: 2019-06-17 Impact factor: 8.989